Attenuation of antimalarial agent hydroxychloroquine on TNF-α-induced endothelial inflammation

International Immunopharmacology

Volumn 63, Issue , 2018, Pages 261-269

  Li, Ruiru ^a   Lin, Haobo ^b   Ye, Yujin ^a   Xiao, Youjun ^a   Xu, Siqi ^a   Wang, Jingnan ^a   Wang, Cuicui ^a   Zou, Yaoyao ^a   Shi, Maohua ^a   Liang, Liuqin ^a   Xu, Hanshi ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Endothelial cells; Hydroxychloroquine; Inflammation; MAPK; NF B

Indexed keywords

HYDROXYCHLOROQUINE; INTERCELLULAR ADHESION MOLECULE 1; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; ANTIINFLAMMATORY AGENT; ANTIMALARIAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INFLAMMATION; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; LUNG INTERSTITIUM; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; CELL ADHESION; CELL CULTURE; DRUG EFFECT; LEUKOCYTE; MAPK SIGNALING; METABOLISM;

ANTI-INFLAMMATORY AGENTS; ANTIMALARIALS; CELL ADHESION; CELLS, CULTURED; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROXYCHLOROQUINE; INTERCELLULAR ADHESION MOLECULE-1; LEUKOCYTES; MAP KINASE SIGNALING SYSTEM; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 85051486605     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2018.08.008     Document Type: Article

References (32)

1. Murdaca, G., Colombo, B.M., Cagnati, P., Gulli, R., Spano, F., Puppo, F., Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 224 (2012), 309–317, 10.1016/j.atherosclerosis.2012.05.013.
2. Nikpour, M., Gladman, D.D., Urowitz, M.B., Premature coronary heart disease in systemic lupus erythematosus: what risk factors do we understand?. Lupus 22 (2013), 1243–1250, 10.1177/0961203313493031.
3. Peters, M.J., van der Horst-Bruinsma, I.E., Dijkmans, B.A., Nurmohamed, M.T., Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin. Arthritis Rheum. 34 (2004), 585–592.
4. Gimbrone, M.A.J., Bevilacqua, M.P., Cybulsky, M.I., Endothelial-dependent mechanisms of leukocyte adhesion in inflammation and atherosclerosis. Ann. N. Y. Acad. Sci. 598 (1990), 77–85.
5. Ley, K., Laudanna, C., Cybulsky, M.I., Nourshargh, S., Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7 (2007), 678–689, 10.1038/nri2156.
6. Steyers, C.M. 3rd, Miller, F.J.J., Endothelial dysfunction in chronic inflammatory diseases. Int. J. Mol. Sci. 15 (2014), 11324–11349, 10.3390/ijms150711324.
7. Kempe, S., Kestler, H., Lasar, A., Wirth, T., NF-kappaB controls the global pro-inflammatory response in endothelial cells: evidence for the regulation of a pro-atherogenic program. Nucleic Acids Res. 33 (2005), 5308–5319, 10.1093/nar/gki836.
8. Molestina, R.E., Miller, R.D., Lentsch, A.B., Ramirez, J.A., Summersgill, J.T., Requirement for NF-kappaB in transcriptional activation of monocyte chemotactic protein 1 by chlamydia pneumoniae in human endothelial cells. Infect. Immun. 68 (2000), 4282–4288.
9. Zhou, Z., Connell, M.C., MacEwan, D.J., TNFR1-induced NF-kappaB, but not ERK, p38MAPK or JNK activation, mediates TNF-induced ICAM-1 and VCAM-1 expression on endothelial cells. Cell. Signal. 19 (2007), 1238–1248, 10.1016/j.cellsig.2006.12.013.
10. Johnson, G.L., Lapadat, R., Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298 (2002), 1911–1912, 10.1126/science.1072682.
11. Hoefen, R.J., Berk, B.C., The role of MAP kinases in endothelial activation. Vasc. Pharmacol. 38 (2002), 271–273.
12. Liang, C.-J., Wang, S.-H., Chen, Y.-H., Chang, S.-S., Hwang, T.-L., Leu, Y.-L., Tseng, Y.-C., Li, C.-Y., Chen, Y.-L., Viscolin reduces VCAM-1 expression in TNF-alpha-treated endothelial cells via the JNK/NF-kappaB and ROS pathway. Free Radic. Biol. Med. 51 (2011), 1337–1346, 10.1016/j.freeradbiomed.2011.06.023.
13. Nizamutdinova, I.T., Oh, H.M., Min, Y.N., Park, S.H., Lee, M.J., Kim, J.S., Yean, M.H., Kang, S.S., Kim, Y.S., Chang, K.C., Kim, H.J., Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways. Int. Immunopharmacol. 7 (2007), 343–350, 10.1016/j.intimp.2006.11.004.
14. Read, M.A., Whitley, M.Z., Gupta, S., Pierce, J.W., Best, J., Davis, R.J., Collins, T., Tumor necrosis factor alpha-induced E-selectin expression is activated by the nuclear factor-kappaB and c-JUN N-terminal kinase/p38 mitogen-activated protein kinase pathways. J. Biol. Chem. 272 (1997), 2753–2761.
15. Becker-Merok, A., Nossent, J., Prevalence, predictors and outcome of vascular damage in systemic lupus erythematosus. Lupus 18 (2009), 508–515, 10.1177/0961203308099233.
16. Kalia, S., Dutz, J.P., New concepts in antimalarial use and mode of action in dermatology. Dermatol. Ther. 20 (2007), 160–174, 10.1111/j.1529-8019.2007.00131.x.
17. Rand, J.H., Wu, X.-X., Quinn, A.S., Chen, P.P., Hathcock, J.J., Taatjes, D.J., Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 112 (2008), 1687–1695, 10.1182/blood-2008-03-144204.
18. Roman, M.J., Shanker, B.-A., Davis, A., Lockshin, M.D., Sammaritano, L., Simantov, R., Crow, M.K., Schwartz, J.E., Paget, S.A., Devereux, R.B., Salmon, J.E., Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349 (2003), 2399–2406, 10.1056/NEJMoa035471.
19. Ravenell, R.L., Kamen, D.L., Spence, J.D., Hollis, B.W., Fleury, T.J., Janech, M.G., Almeida, J.S., Shaftman, S.R., Oates, J.C., Premature atherosclerosis is associated with hypovitaminosis D and angiotensin-converting enzyme inhibitor non-use in lupus patients. Am J Med Sci 344 (2012), 268–273, 10.1097/MAJ.0b013e31823fa7d9.
20. Long, L., Yang, X., Southwood, M., Lu, J., Marciniak, S.J., Dunmore, B.J., Morrell, N.W., Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation. Circ. Res. 112 (2013), 1159–1170, 10.1161/CIRCRESAHA.111.300483.
21. Gomez-Guzman, M., Jimenez, R., Romero, M., Sanchez, M., Zarzuelo, M.J., Gomez-Morales, M., O'Valle, F., Lopez-Farre, A.J., Algieri, F., Galvez, J., Perez-Vizcaino, F., Sabio, J.M., Duarte, J., Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus. Hypertension (Dallas, Tex. 1979) 64 (2014), 330–337, 10.1161/HYPERTENSIONAHA.114.03587.
22. Rahman, R., Murthi, P., Singh, H., Gurusinghe, S., Mockler, J.C., Lim, R., Wallace, E.M., The effects of hydroxychloroquine on endothelial dysfunction. Pregnancy Hypertens. 6 (2016), 259–262, 10.1016/j.preghy.2016.09.001.
23. Chang, S.W., Ohara, N., Kuo, G., Voelkel, N.F., Tumor necrosis factor-induced lung injury is not mediated by platelet-activating factor. Am. J. Phys. 257 (1989), L232–L239, 10.1152/ajplung.1989.257.4.L232.
24. Dreymueller, D., Martin, C., Kogel, T., Pruessmeyer, J., Hess, F.M., Horiuchi, K., Uhlig, S., Ludwig, A., Lung endothelial ADAM17 regulates the acute inflammatory response to lipopolysaccharide. EMBO Mol. Med. 4 (2012), 412–423, 10.1002/emmm.201200217.
25. Hou, J., Baichwal, V., Cao, Z., Regulatory elements and transcription factors controlling basal and cytokine-induced expression of the gene encoding intercellular adhesion molecule 1. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 11641–11645.
26. Manning, A.M., Bell, F.P., Rosenbloom, C.L., Chosay, J.G., Simmons, C.A., Northrup, J.L., Shebuski, R.J., Dunn, C.J., Anderson, D.C., NF-kappa B is activated during acute inflammation in vivo in association with elevated endothelial cell adhesion molecule gene expression and leukocyte recruitment. J. Inflamm. 45 (1995), 283–296.
27. Mathieu, S., Motreff, P., Soubrier, M., Spondyloarthropathies: an independent cardiovascular risk factor?. Joint Bone Spine 77 (2010), 542–545, 10.1016/j.jbspin.2010.05.001.
28. Singh, S., Singh, H., Loftus, E.V.J., Pardi, D.S., Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 12 (2014), 382–393 e1: quiz e22 https://doi.org/10.1016/j.cgh.2013.08.023.
29. Gelfand, J.M., Neimann, A.L., Shin, D.B., Wang, X., Margolis, D.J., Troxel, A.B., Risk of myocardial infarction in patients with psoriasis. JAMA 296 (2006), 1735–1741, 10.1001/jama.296.14.1735.
30. Hansson, G.K., Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352 (2005), 1685–1695, 10.1056/NEJMra043430.
31. Bonetti, P.O., Lerman, L.O., Lerman, A., Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol. 23 (2003), 168–175.
32. Davignon, J., Ganz, P., Role of endothelial dysfunction in atherosclerosis. Circulation 109 (2004), III27–32, 10.1161/01.CIR.0000131515.03336.f8.